cytophage.com
Get leads like Cytophage — and thousands more
Build targeted lists by tech stack, traffic, and more
Cytophage: The Post-Antibiotic Era Has Arrived
Why this 22-person biotech startup is targeting a $100B crisis with nature's oldest predator
By 2050, superbugs will kill 10 million people annually—more than cancer. While Big Pharma chases incremental antibiotics, Cytophage is weaponizing bacteriophages, the natural predators bacteria have feared for billions of years, to solve the antibiotic resistance crisis once and for all.
"We're not building a better antibiotic. We're deploying a living therapy that evolves faster than bacteria can adapt."
The Market No One Saw Coming
The antibiotic resistance market is exploding from $9B to a projected $100B+ by 2030. Traditional pharma giants have abandoned antibiotic R&D—it's a financial black hole. Cytophage saw an opening: bacteriophages are self-replicating, highly specific, and environmentally harmless. Their 'bacterio-matched' approach means therapy tailored to each patient's specific bacterial strain, a precision medicine play that antibiotics simply cannot match.
The Team That Matters
With just 22 employees, Cytophage punches above its weight. CEO Steven Theriault leads a lean, specialized bench of scientists including Tasia Lightly (Staff Scientist) and Nicolas Fournier (Research Associate). This isn't a bloated pharma operation—it's a focused biotech weapon designed for speed and agility. Their team structure signals they're still in pure R&D mode, but executing with military precision.
Cytophage's digital presence reveals a company straddling two worlds: deep science and investor storytelling. Their 2,428 monthly visits aren't massive, but the 41% organic search share shows they're capturing high-intent researchers and investors searching 'phage therapy' (4,020 monthly searches) and 'bacteriophage' (34,110 monthly searches). The real signal? Their YouTube content and TMX stock page indicate they're preparing for capital markets attention.
- Bacterio-matched therapy: Each treatment is customized to the patient's specific bacterial strain
- Sustainable by design: Phages leave human cells and beneficial bacteria untouched
- Countless applications: From hospital-acquired infections to agricultural pathogens
- Regulatory runway: Positioned for FDA approval pathways for phage-based therapies
The Bottom Line
Cytophage isn't betting on antibiotics 2.0—they're betting antibiotics are obsolete. With $3.4M in revenue and a team of 22 scientists, they're building the infrastructure for a post-antibiotic world while Big Pharma still hasn't noticed. For investors, this is a high-risk, high-reward play on the single biggest healthcare crisis of our lifetime.
What tech stack does Cytophage use?
How much traffic does Cytophage get?
Traffic & Engagement
Traffic Sources
Where is Cytophage's audience located?
What keywords does Cytophage rank for?
5 keywordsHow is Cytophage's SEO?
Meta Tags
Home - Cytophage
The world’s first sustainable solution to bacterial infection and disease. https://youtu.be/wjwCQ7sw3kg Get Cytophage Investor Alerts One BreakthroughHighlySafe & EffectiveCountless Applications Watch the video to learn more about Cytophage https://cytophage.com/wp-content/uploads/2021/10/Cytophage_MatterofFact_2021_Final_WebQualitysmall.mp4 Future Safe By 2050, the World Health Organizations predicts that 10 million people a year will be killed by antibiotic resistant superbugs. However, with our bacterio-matched
H1 Tags
Schema Types
What is Cytophage's revenue?
Who competes with Cytophage?
Who works at Cytophage?
Loading leads...
What do customers think of Cytophage?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Cytophage
What is Cytophage's Revenue?
What does Cytophage do?
How fast is Cytophage growing?
What technologies does Cytophage use?
Who are Cytophage's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Cytophage?
Export cytophage.com Data
Download the complete tech stack, analytics, leads, and company data for cytophage.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About cytophage.com
The world’s first sustainable solution to bacterial infection and disease. https://youtu.be/wjwCQ7sw3kg Get Cytophage Investor Alerts One BreakthroughHighlySafe & EffectiveCountless Applications Watch the video to learn more about Cytophage https://cytophage.com/wp-content/uploads/2021/10/Cytophage_MatterofFact_2021_Final_WebQualitysmall.mp4 Future Safe By 2050, the World Health Organizations predicts that 10 million people a year will be killed by antibiotic resistant superbugs. However, with our bacterio-matched
Company Overview
cytophage.com Social Media
Contact cytophage.com
Technology Stack
cytophage.com uses 12 technologies across their website including YouTube Embed, Font Awesome, PHP, and more.
Video
YouTube Embed
Fonts
Font Awesome
Programming Languages
PHP
CMS
WordPress
Analytics & Marketing
Google Analytics
Performance
Priority Hints
Traffic & Audience
cytophage.com receives approximately 2.4K monthly visitors and ranks #7,966,560 globally. The website has a bounce rate of 36% with visitors viewing an average of 1.1 pages per visit. Users spend an average of 0:00 on the site.
The majority of cytophage.com's traffic comes from undefined, undefined, .
Frequently Asked Questions
What is cytophage.com?
What technologies does cytophage.com use?
How do I contact cytophage.com?
What are cytophage.com's social media accounts?
How popular is cytophage.com?
Related Searches
This page provides publicly available information about cytophage.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit cytophage.com directly at https://cytophage.com.